The oral KIF11 inhibitor 4SC‐205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models

The oral KIF11 inhibitor 4SC‐205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models

Bibliographic Details
Main Authors: Marc Masanas, Nuria Masiá, Leticia Suárez‐Cabrera, Mireia Olivan, Aroa Soriano, Blanca Majem, Laura Devis‐Jauregui, Rebeca Burgos‐Panadero, Carlos Jiménez, Pau Rodriguez‐Sodupe, Ariadna Boloix, Ignasi Toledano, Gabriela Guillén, Alexandra Navarro, David Llobet‐Navas, Alberto Villanueva, Josep Sánchez de Toledo, Josep Roma, Rosa Noguera, Lucas Moreno, Rolf Krauss, Soledad Gallego, Anna Santamaria, Miguel F. Segura
Format: Article
Language:English
Published: Wiley 2021-10-01
Series:Clinical and Translational Medicine
Online Access:https://doi.org/10.1002/ctm2.533

Similar Items

Similar Items